1. Home
  2. SRI vs LYEL Comparison

SRI vs LYEL Comparison

Compare SRI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stoneridge Inc.

SRI

Stoneridge Inc.

HOLD

Current Price

$6.22

Market Cap

205.1M

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$7.74

Market Cap

213.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRI
LYEL
Founded
1965
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
205.1M
213.4M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
SRI
LYEL
Price
$6.22
$7.74
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $37.88
AVG Volume (30 Days)
★ 155.1K
139.5K
Earning Date
11-04-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $824,444,000.00
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.90
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 18.46
N/A
52 Week Low
$4.60
$8.21
52 Week High
$9.71
$45.00

Technical Indicators

Market Signals
Indicator
SRI
LYEL
Relative Strength Index (RSI) 29.33 19.53
Support Level $6.14 N/A
Resistance Level $7.51 $15.38
Average True Range (ATR) 0.22 0.51
MACD -0.05 -0.04
Stochastic Oscillator 4.40 1.97

Price Performance

Historical Comparison
SRI
LYEL

About SRI Stoneridge Inc.

Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Geographically, the company generates key revenue from the United States.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: